Florfenicol, mometasone furoate, terbinafine (Neptra Ear)
Florfenicol, mometasone furoate, terbinafine
Elanco Animal Health (Pty) Ltd
Registration
- Applicant
- Elanco Animal Health (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Neptra ear drops EACH 1,0 ml LIQUID CONTAINS FLORFENICOL 16,6 mg MOMETASONE FUROATE 2,2 mg TERBINAFINE HYDROCHLORIDE 16,6 mg | Drops | 20/0620/14.3/06 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Florfenicol
Consolidated Schedules 06 July 2026, line 6345
S4: Mometasone furoate
- except when intended for inhalation or nasal administration.
Consolidated Schedules 06 July 2026, line 7167
S4: Terbinafine
- except when intended for application to the skin.
Consolidated Schedules 06 July 2026, line 8132
S3: Mometasone furoate
- when intended for inhalation or nasal administration, except when intended for nasal administration as an aqueous spray, other than by pressurized aerosol, and indicated for the treatment of the symptoms of seasonal or perennial allergic rhinitis (hay fever) in adults and children between the age of 2 and 11 years of age, subject to
- a maximum dose of 200 micrograms per nostril in adults and 50 micrograms per nostril in children; and
- a maximum pack size of 200 doses. (S2, S4)
Consolidated Schedules 06 July 2026, lines 3960 to 3965
S2: Mometasone furoate
- when intended for nasal administration as an aqueous spray, other than by pressurized aerosol, and indicated for the treatment of the symptoms of seasonal or perennial allergic rhinitis (hay fever) in adults and children between the age of 2 and 11 years of age, subject to
- a maximum dose of 200 micrograms per nostril in adults and 50 micrograms per nostril in children; and
- a maximum pack size of 200 doses. (S3, S4)
Consolidated Schedules 06 July 2026, lines 2284 to 2290
S1: Terbinafine
- when intended for application to the skin.
Consolidated Schedules 06 July 2026, line 1094
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.